(Q35058707)

6 August 2017

title

Advanced-phase chronic myeloid leukemia (English)

1 reference

6 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

2

Hagop Kantarjian

1 reference

6 August 2017

1

Jorge Cortes

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

published in

Seminars in Hematology

1 reference

6 August 2017

volume

40

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

79-86

1 reference

RAS and leukemia: from basic mechanisms to gene-directed therapy

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Significance of cytogenetic clonal evolution in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

The cytogenetic scenario of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2803%2970045-6

7 January 2021

10.1016/S0037-1963(03)70045-6

Identifiers

DOI

1 reference

6 August 2017

1 reference